Imcyse is a Belgian biotech company founded by Professor Jean-Marie Saint-Remy in July 2010. The company work is based on proprietary technology platform with the work done by its research study group based at the Catholic University of Leuven (KUL) also known as the University of Leuven, Belgium. The company is going to launch a Phase Ib trial in type 1 diabetes (T1D) patients as the company got approval from British and Belgian regulatory authorities. The European Union through EXALT program is funding the study.
The first Imcyse's immunotherapy technology trial among humans is going to be conducted in 18 sites across Belgium, Denmark, Germany, France and UK. French Inserm is the French National Institute of Health and Medical Research and Imcyse is going to collaborate with Inserm in conducting trials. Imcyse's immunotherapy technology is intended to stop the death of beta cells in the pancreas which produces insulin in patients diagnosed with type 1 diabetes (T1D). The trial results are expected during 2018.
Existing therapies or treatments can either reduce the symptoms of type 1 diabetes (T1D) or slowdown the progress of type 1 diabetes (T1D). But immunotherapy technology from Imcyse aims to cure type 1 diabetes (T1D). Transplantation of beta cells which is under developmental stage is the other option to treat type 1 diabetes (T1D).
Tim Lui Hin-wai, a biomedical engineer, aged 27 years co-founder of Heartisans, a Hong Kong based technology start-up company. He developed a mobile App and a Smartwatch, a wearable technology device which can predict heart attacks up to 10 minutes before it is going to happen. This device was developed specifically for heart disease and high blood pressure BP (or hypertension) patients.
The Smartwatch contains an electrocardiogram (ECG) sensor that can read heart electrical activity and pass the information to accompanying mobile App. The App analyzes the readings of the Smartwatch continuously and alerts the users about the imminent development of coronary artery disease if it is going to strike. Some of the features of the Smartwatch wearable device are
The wearable Smartwatch is under testing process at Queen Mary Hospital, Hong Kong with heart attack patients who experienced heart attack previously and likely to face heart attack again. Knowing the heart attack up to 10 minutes before it strikes can save a life of the patient. Tim Lui Hin-wai is planning another large trial involving 600 individuals to check congestive heart failure. They are planning to monitor the development of the congestive heart failure and effects of the treatments over the heart. Duration of the study is two years.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.